News & Updates

Show Multimedia Only
GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD
GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD
17 Jun 2025 byStephen Padilla

In paediatric patients with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), treatment with GLP-1 receptor agonists (RAs) results in a decrease in depression and substance use, as shown in a study presented at ESPGHAN 2025.

GLP-1 RAs reduce depression, substance use in young patients with obesity, MASLD
17 Jun 2025
Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care
Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care
13 Jun 2025 byNatalia Reoutova

Lifestyle modification induced remission of metabolic dysfunction–associated steatotic liver disease (MASLD) in a higher proportion of people living with HIV (PLHIV) than standard care, according to the first randomized controlled trial (RCT) of its kind conducted by researchers from the Chinese University of Hong Kong (CUHK).

Lifestyle modification resolves MASLD, improves adiposity in more PLHIV than standard care
13 Jun 2025
Are statins protective against HCC?
Are statins protective against HCC?
10 Jun 2025